Pediatric ulcerative colitis associated with autoimmune diseases: A distinct form of inflammatory bowel disease?

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1809-1817

  Ordonez, Felipe ^a   Lacaille, Florence ^a   Canioni, Danielle ^a   Talbotec, Cecile ^a   Fournet, Jean Christophe ^a   Cerf Bensussan, Nadine ^a   Goulet, Olivier ^a   Schmitz, Jacques ^a   Ruemmele, Frank M ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

autoimmune; pediatric; primary sclerosing cholangitis; ulcerative colitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 8; MESALAZINE; NEUTROPHIL CYTOPLASMIC ANTIBODY; SALAZOSULFAPYRIDINE; SMOOTH MUSCLE ANTIBODY; THYMIC STROMAL LYMPHOPOIETIN; TRANSCRIPTION FACTOR FOXP3; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BLOODY DIARRHEA; CELIAC DISEASE; CELL INFILTRATION; CHILD; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL FEATURE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; EOSINOPHIL; FEMALE; HEMATOCHEZIA; HLA TYPING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; MAINTENANCE THERAPY; MALE; PANCOLITIS; PORTAL HYPERTENSION; PRESCHOOL CHILD; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; ULCERATIVE COLITIS;

ADOLESCENT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; FEMALE; HUMANS; INFANT; LIVER DISEASES; MALE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84861330131     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22864     Document Type: Article

References (56)

1. Kugathasan S, Amre D,. Inflammatory bowel disease-environmental modification and genetic determinants. Pediatr Clin North Am. 2006; 53: 727-749. (Pubitemid 44109714)
2. Abraham C, Cho JH,. Inflammatory bowel diseases. N Engl J Med. 2009; 361: 2066-2076.
3. Ruemmele F,. Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol. 2010; 26: 332-336.
4. Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell. 2008; 134: 743-756.
5. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004; 113: 1490-1497. (Pubitemid 39071705)
6. Sartor RB,. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008; 134: 577-594. (Pubitemid 351173057)
7. Barnes MJ, Powrie F,. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009; 31: 401-411.
8. Maynard CL, Harrington LE, Janowski KM, et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol. 2007; 8: 931-941. (Pubitemid 47300007)
9. Bamias G, Cominelli F,. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr Opin Gastroenterol. 2007; 23: 365-369. (Pubitemid 46878946)
10. Saarinen S, Olerup O, Broome U,. Increased frequency of autoimmune disease in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000; 95: 3195-3199.
11. Terrier B, Fontaine H, Schmitz J, et al. Coexistence and parallel evolution of hypereosinophilic syndrome, autoimmune hepatitis, and ulcerative colitis suggest common pathogenic features. Am J Gastroenterol. 2007; 102: 1132-1134. (Pubitemid 46698254)
12. Raj V, Lichtenstein D,. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am. 1999; 28: 491-513. (Pubitemid 29306490)
13. Faubion WA, Loftus EV, Sandborn WJ, et al. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J Pediatr Gastroenterol Nutr. 2001; 33: 296-300. (Pubitemid 32947333)
14. Kawa S, Hamano H, Umemura T, et al. Sclerosing cholangitis associated with autoimmune pancreatitis. Hepatol Res. 2007; 37 (Suppl 3): S487-495. (Pubitemid 47570664)
15. Yang A, Chen Y, Scher El, et al. Inflammatory bowel disease in patients with celiac disease. Inflamm Bowel Dis. 2005; 11: 528-532. (Pubitemid 40826339)
16. Leeds JS, Hörolldt BS, Sidhu R, et al. Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls. Scand J Gastroenterol. 2007; 42: 1214-1220. (Pubitemid 47537092)
17. Gordon,. Primary sclerosing cholangitis. Surg Clin N Am. 2008; 88: 1385-1407.
18. Wilschanski M, Chait P, Wade JA, et al. Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic feature, with survival analysis. Hepatology. 1995; 22: 1415-1422.
19. Feldstein AE, Perreault J, El-Youssif M, et al. Primary sclerosing cholangitis in children: a long term folow-up study. Hepatology. 2003; 38: 210-217. (Pubitemid 36775813)
20. Stenhammar L, Högberg L, Lewander P,. Primary sclerosing cholangitis on childhood inflammatory bowel disease. Arch Dis Child. 1994; 71: 281-283.
21. Saich R, Chapman R,. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 331-337. (Pubitemid 351320842)
22. Audan A, Bruley Des Varannes S, Georgelin T, et al. Primary sclerosing cholangitis and systemic lupus erythematosus. Gastroenterol Clin Biol. 1995; 19: 123-126.
23. Ahmad J, Slivka A,. Hepatobiliary disease in inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31: 329-345. (Pubitemid 34733049)
24. Broome U, Berquist A,. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006; 26: 31-41. (Pubitemid 43320725)
25. Lundqvist K, Broome U,. Difference in colonic disease activity in patients with ulcerative colitis wtih and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum. 1997; 40: 451-456. (Pubitemid 27172624)
26. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis: the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41: 1-7.
27. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris Classification. Inflamm Bowel Dis. 2011; 17: 1314-1321.
28. Pfaffl MW,. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29: e45.-
29. LaRusso NF, Schneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. Hepatology. 2006; 44: 746-764. (Pubitemid 44433732)
30. Alvarez F,. Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis. 2006; 10: 89-107. (Pubitemid 41821379)
31. Lacaille F, Canioni D, Bernard O, et al. Celiac disease, inflammatory colitis, and primary sclerosing cholangitis in a girl with Turner's syndrome. J Pediat Gastroenterol Nutr. 1995; 21: 463-467.
32. Miloh T, Arnon R, Schneider B, et al. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol. 2009; 7: 239-245.
33. Banki DS, Fleming KA, Chapman RW,. Importance of antineutrophil cytoplasmatic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre and IgG subclass. Gut. 1996; 38: 384-389. (Pubitemid 26074319)
34. Banki DS, Chapman RW, Fleming KA,. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1996; 8: 881-885. (Pubitemid 26319391)
35. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16 year prospective study. Hepatology. 2001; 33: 544-553. (Pubitemid 32185215)
36. Mulder AH, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver disease. Hepatology. 1993; 17: 411-417. (Pubitemid 23072815)
37. Vierling JM,. Is primary sclerosing cholangitis an autoimmune disease? In:, Leuschner U, Broome' U, Stiehl A, eds. Cholestatic Liver Diseases: Therapeutic Options & Perspectives. Dordrecht, Netherlands: Kluwer Academic Publishers. 2004; 24: 243-246.
38. Cullen SN, Chapman RW,. Primary sclerosing cholangitis. Autoimmun Rev. 2003; 2: 305-312.
39. Donaldson PT,. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004; 53: 599-608. (Pubitemid 38372988)
40. Olsson R, Danielsson A, Jänerot G, et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1999; 100: 1319-1323.
41. Loftus EV Jr, Harewood GC, Loftus CG, et al. "PSC IBD": a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005; 54: 91-96. (Pubitemid 40007225)
42. Hyams JS, Davis P, Grancher K, et al. Clinical outcome of ulcerative colitis in children. J. Pediatr. 1996; 129: 81-88. (Pubitemid 26277250)
43. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003; 124: 889-893. (Pubitemid 36389790)
44. Charatcharoenwitthata P, Angulo P, Enders FB, et al. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology. 2008; 47: 133-142. (Pubitemid 351171050)
45. Golger MA, Gann ME, Opekun AR, et al. Efficay of ursodeoxycholic acid in the treatement of primary sclerosing cholingitis in children. J Pediatr Gastroenterol Nutr. 2000; 31: 136-141. (Pubitemid 30618302)
46. Shkoda A, Ruiz PA, Daniel H, et al. Interleukin-10 blocked endoplasmic reticulum stress in intestinal epithelial cells: impact on chronic inflammation. Gastroenterology. 2007; 132: 190-207. (Pubitemid 46108743)
47. Clevers H,. Inflammatory bowel disease, stress and the endoplasmic reticululm. N Engl J Med. 2009; 360: 726-727.
48. Chaudhry A, Samstein RM, Treuting P, et al. Interleukin 10 signaling in regulatory T cells is required for suppression of the 17 cell mediated inflammation. Immunity. 2011; 34: 566-578.
49. Ruemmele FM, Moes N, Patey-Mariaud de Serre N, et al. Clinical and molecular aspects of autoimmune enteropathy and IPEX-syndrome. Curr Opin Gastroenterol. 2008; 24: 742-748.
50. Moes N, Rieux-Laucat F, Begue B, et al. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology. 2010; 139: 770-778.
51. Ochs H, Gambineri E, Torgerson TR,. IPEX, FOXP3 and regulatory T cells: a model for autoimmunity. Immunol Res. 2007; 38: 112-121. (Pubitemid 47574902)
52. Ziegler SF, Artis D,. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010; 11: 289-293.
53. Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005; 202: 1213-1223. (Pubitemid 41586952)
54. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009; 361: 2033-2045.
55. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL10 signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol. 2011; 106: 1544-1555.
56. Zimmermann N, Hershey GK, Foster PS, et al. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol. 2003; 111: 227-242.